Mechanism of Action: Beyond Tyrosinase Inhibition

TXA exerts its anti-melanogenic effects through a multi-pathway mechanism distinct from conventional tyrosinase inhibitors. The primary pathway involves inhibition of the plasminogen–plasmin system in keratinocytes. Ultraviolet radiation upregulates plasmin activity in the epidermis, which releases arachidonic acid and prostaglandin E₂ — both potent stimulators of melanogenesis through paracrine signalling to melanocytes. By competitively binding to lysine sites on plasminogen, TXA interrupts this cascade without directly inhibiting tyrosinase, making it compatible with ascorbic acid and other pH-sensitive actives.

A 2024 study published in the Annals of Dermatology (PMID: 38816976) identified a second critical mechanism: suppression of endothelin-1 (ET-1) secretion from dermal microvascular endothelial cells. ET-1 is a potent melanogenic cytokine released in UV-irradiated skin, and its downregulation by TXA reduces melanocyte proliferation independent of the tyrosinase pathway. The same study confirmed that TXA also reduces stem cell factor (SCF) levels, addressing two distinct upstream triggers of hyperpigmentation simultaneously.

In 2025, Bae et al. published findings in Experimental Dermatology (doi: 10.1111/exd.70194) demonstrating a third mechanism — direct inhibition of 17β-estradiol-induced melanogenesis via the PKA-CREB-MITF signalling axis. This is clinically significant because oestrogen is a well-documented melasma trigger. TXA attenuates cAMP-dependent PKA-CREB signalling, reducing microphthalmia-associated transcription factor (MITF) expression and consequently suppressing TYR, TRP-1, and TRP-2 gene transcription. The net result is multi-pronged pigment suppression without melanocyte cytotoxicity.

Effective Concentration Range: What the Evidence Shows

Clinical evidence supports a topical TXA concentration range of 2%–5%. A pilot study by Ertam et al. published in Cosmetics (2024;11:168) evaluated a 3% TXA cream in Caucasian patients with facial hyperpigmentation and found statistically significant MASI reductions at 12 weeks. Critically, this study reported no detectable systemic absorption at the 3% concentration, addressing concerns about the ingredient’s procoagulant properties in topical use.

When compared head-to-head against hydroquinone, TXA holds its ground. A split-face randomised controlled trial by Banihashemi et al. (J Dermatol Treat) demonstrated that 5% liposomal TXA achieved MASI reductions comparable to 4% hydroquinone over 12 weeks, with notably fewer adverse events — hydroquinone produced irritation in three of 23 participants, while TXA produced none. A 2025 meta-analysis encompassing 10 RCTs and 455 participants confirmed a moderate pooled effect size (Hedges’ g = 0.477) for TXA across oral, topical, and injectable routes.

Formulation Challenges and How to Solve Them

Challenge 1: TXA’s Hydrophilicity

TXA has a log P of approximately −2.0, making it highly water-soluble and poorly partition-prone through the stratum corneum lipid matrix. Simple aqueous solutions deliver insufficient epidermal retention. The solution is lipid-based or vesicular delivery systems.

Solution: Lipidic Vesicular Carriers

A 2025 systematic review by Soo et al. in Advanced Pharmaceutical Bulletin (15:574–587) examined lipidosomes, ethosomes, and niosomes for TXA delivery. All three systems significantly outperformed aqueous controls in epidermal and dermal drug retention. Niosomal carriers — non-ionic surfactant vesicles — emerged as particularly cost-effective for scale-up while delivering comparable penetration to liposomes. A 2025 randomised controlled trial by Ghasemiyeh et al. in Scientific Reports (doi: 10.1038/s41598-025-42739-1) confirmed that niosomal TXA/niacinamide cream performed comparably to hydroquinone 4% in melasma patients with superior tolerability.

Challenge 2: pH Sensitivity of Co-Actives

TXA is most stable in the pH range of 4.5–6.0. Formulators should avoid co-formulating with high-concentration ascorbic acid (optimal pH 2.5–3.5) in the same aqueous phase, as the pH incompatibility will compromise both ingredients. Instead, use a two-product protocol: apply ascorbic acid serum first, allow 60–90 seconds for absorption, then layer the TXA formulation on top. Alternatively, formulate TXA in a separate product entirely.

Challenge 3: Preservative Selection

Because TXA is hydrophilic and typically used at 3–5% in the water phase, the preservative system must be both effective against a broad microbial spectrum and compatible with the active. Phenoxyethanol at 0.7–1.0% in combination with ethylhexyllycerin (0.3–0.5%) provides broad-spectrum preservation without pH drift and is compatible with TXA across the recommended pH window. Avoid parabens in markets with growing consumer preference against them.

Synergistic Combinations for Multi-Pathway Therapy

The most effective TXA-based formulations target multiple points in the melanogenesis cascade simultaneously. Research consistently supports the following high-value combinations:

• TXA + Niacinamide (5%): TXA interrupts melanogenesis upstream via the plasmin pathway; niacinamide inhibits melanosome transfer from melanocytes to keratinocytes. A 2024 clinical study using a 3% TXA + 5% niacinamide cream demonstrated MASI improvements comparable to combination hydroquinone–corticosteroid formulations in melasma patients.
• TXA + Azelaic Acid (10–15%): Azelaic acid inhibits tyrosinase directly and reduces oxidative stress; TXA addresses the keratinocyte–melanocyte signalling axis. Both are pregnancy-safe in most markets, making this combination valuable for clinicians managing melasma in pregnant or lactating patients.
• TXA + Licorice Root Extract (Glabridin): Glabridin inhibits tyrosinase and has demonstrated anti-inflammatory properties; TXA addresses plasmin-mediated signalling. The combination is particularly effective for post-inflammatory hyperpigmentation.

Step-by-Step: Formulating a 3% TXA Brightening Serum

The following is a conceptual base formula for a stable, consumer-friendly TXA serum targeting melasma and post-inflammatory hyperpigmentation. Adjust percentages based on your target market’s regulatory limits and stability testing requirements.

Process notes: Dissolve TXA and niacinamide separately in the water phase at room temperature (avoid heating, as both are heat-stable but unnecessary). Adjust pH to 5.0–5.5 using sodium hydroxide solution (10% w/v). Target a final viscosity of 500–2,000 cPs for a light serum texture. Package in airless pump or dropper bottle to minimise oxidation risk and ensure dose accuracy.

Regulatory Landscape for TXA in Key Markets

In Japan, topical TXA holds formal drug indication status for melasma. In the EU, TXA is listed in the CosIng database for cosmetic use, though regulatory guidance varies by member state. In the US, TXA remains prescription-only for dermatological use under the CARE Act (2020), limiting its cosmetic availability — though this has not stopped the growth of compounded and professional-use formulations. For Southeast Asian markets — where melasyl.com targets — TXA’s status is generally permissive: Thailand, Singapore, and Malaysia permit topical TXA in cosmetic formulations up to 3%, making it an excellent choice for this region’s market.

Conclusion

Tranexamic acid is no longer a niche ingredient waiting for wider recognition. Its multi-pathway anti-melanogenic mechanism — plasmin inhibition, ET-1 suppression, and PKA-CREB-MITF axis modulation — positions it as a scientifically sophisticated alternative to hydroquinone for formulators developing brightening and anti-melasma products. The key formulation decisions — concentration (2–5%), delivery system (lipidic vesicular preferred), pH window (4.5–6.0), and co-active selection — are well-supported by clinical evidence and represent a genuine opportunity to produce differentiated, market-ready products for the Southeast Asian consumer base.